Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y Wang, Chong Won Sung, Céline Dartois et al. · Clinical Pharmacology & Therapeutics · 2009
Four non-small-cell lung cancer (NSCLC) registration trials were utilized to develop models linking survival to risk factors and changes in tumor size during treatment. The purpose was to leverage existing quantitative knowledge to facilitate future development of anti-NSCLC drugs. Eleven risk factors were screened using a Cox model. A mixed exponential decay and linear growth model was utilized for modeling tumor size. Survival times were described in a parametric model. Eastern Cooperative Oncology Group (ECOG) score and baseline tumor size were consistent prognostic factors of survival. Tumor size was well described by the mixed model. The parametric survival model includes ECOG score, baseline tumor size, and week 8 tumor size change as predictors of survival duration. The change in tumor size at week 8 allows early assessment of the activity of an experimental regimen. The survival model and the tumor model will be beneficial for early screening of candidate drugs, simulating NSCLC trials, and optimizing trial designs.
Cited by 229 works. doi:10.1038/clpt.2009.64
Authors
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Can the pharmaceutical industry reduce attrition rates?
- End Points and United States Food and Drug Administration Approval of Oncology Drugs
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
- Prognostic Factors in Non-small Cell Lung Cancer
- Correlation of Tumor Size and Survival in Patients With Stage IA Non-small Cell Lung Cancer
- Predicting the course of Gompertzian growth